A
Aspect Biosystems
Commercializing cutting-edge bioprinting technologies
About Aspect Biosystems
Aspect Biosystems is a pioneering company in the field of regenerative medicine, specializing in the development of bioprinted tissue therapeutics. The company operates in the biotechnology and pharmaceutical markets, serving clients that include leading pharmaceutical and biotechnology firms. Aspect Biosystems utilizes a transformative platform technology that combines proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design to create allogeneic tissue therapeutics. This innovative approach aims to address some of the most significant challenges in regenerative medicine by developing a targeted pipeline of bioprinted tissue therapeutics.
Read full description
Aspect Biosystems' business model focuses on strategic collaborations and partnerships with top-tier pharmaceutical and biotechnology companies. The company generates revenue through these collaborations, as well as through securing significant funding from investors. Under the leadership of co-founder and CEO Tamer Mohamed, Aspect Biosystems has built a world-class team and secured substantial financial backing to advance its mission.
The company is headquartered in Vancouver, BC, Canada, and offers a range of employee benefits, including competitive salaries, stock options, fully paid extended healthcare, life insurance, and professional development opportunities.
At a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Vancouver, Canada
- Employees
- 145
- Open positions
- 8
- Dealroom signal
- 90.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, 3D Printing, Biotechnology, Biomaterials, Tissue Engineering, Spinout, organ-on-chip, DT and LS, science-based
- Technology
- 3D Technology, Deep Tech
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Aspect Biosystems.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PROJECT, REAL ESTATE, INFRASTRUCTURE FINANCEOther financing | Apr 2026 | $58M | — | Innovation, Science and Economic Development Canada | ↗ |
| SERIES BOther financing | Jan 2025 | $115M | $460M | Novo Nordisk · Pallasite Ventures · Radical Ventures · Pangaea Ventures | ↗ |
Growth signals
Latest recorded traffic for Aspect Biosystems is 14K monthly website visits, down 22.2% over the last three months. Aspect Biosystems's team grew 18.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Innovation UBC
E-Fund
PacifiCan
Government of Canada
Government of British Columbia
Series A19 investors entered at this stage
Pallasite Ventures
Pangaea Ventures
Endure Capital
Relentless Pursuit Partners
Genome British Columbia
Radical Ventures
Hedgewood
Rhino Ventures- SASaad AlSogair
- TWTom Williams
- EPErik Peterson
- KIKILAUEA INVESTMENTS
Cascadia Venture Forum
Page One Ventures- HBHein Brand
Dimension
Novo Nordisk
JDRF T1D Fund
Industrial and Commercial Bank of China
Other known investors2 additional known investors
Innovation, Science and Economic Development Canada
The University of British Columbia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aspect Biosystems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aspect Biosystems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.